Terlipressin effect on hepatorenal syndrome: Updated meta‐analysis of randomized controlled trials

Terlipressin effect on hepatorenal syndrome: Updated meta‐analysis of randomized controlled trials

Abstract Background and Aim Hepatorenal syndrome (HRS) is a fatal complication of liver cirrhosis with a limited pharmacological option. Terlipressin is a vasoconstrictor that is approved in many countries but not yet in the United States. This is a meta‐analysis of randomized controlled trials (RCT...

Full description

Bibliographic Details
Main Authors: Mohamed M G Mohamed, Abdul Rauf, Abubakr Adam, Babikir Kheiri, Alexandre Lacasse, Hani El‐Halawany
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:JGH Open
Subjects:
albumin
cirrhosis
hepatorenal syndrome
terlipressin
Online Access:https://doi.org/10.1002/jgh3.12600

Similar Items

Similar Items